JNJ vs MRK
Johnson & Johnson and Merck & Co., both Healthcare
Johnson & Johnson is the larger company at $550B against $281B. On trailing earnings JNJ is the cheaper of the two at a P/E of 30.3 against 115.5, a gap that is only a bargain if the two are growing at similar rates. Over the past year MRK returned +83% against +53% for JNJ. The RyuScore puts MRK ahead, 78 against 69 out of 100.
| Figure | JNJ | MRK |
|---|---|---|
| Last close | $261 | $146 |
| Market cap | $550B | $281B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 30.3 | 115.5 |
| Dividend yield | 2.0% | 2.3% |
| 1-year return | +53% | +83% |
| 5-year return | +80% | +132% |
| RyuScoresector-relative, 1–10 | 69/100 | 78/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Johnson & Johnson
Revenue of $25B in Q2 2026, net income $5.5B. Its largest reported line is DARZALEX, 19% of the disclosed total.
Merck & Co.
Revenue of $17B in Q2 2026, net income null. Its largest reported line is Keytruda, 49% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.